BR9813757A - Sag : sensìvel a gene de apoptose - Google Patents

Sag : sensìvel a gene de apoptose

Info

Publication number
BR9813757A
BR9813757A BR9813757-3A BR9813757A BR9813757A BR 9813757 A BR9813757 A BR 9813757A BR 9813757 A BR9813757 A BR 9813757A BR 9813757 A BR9813757 A BR 9813757A
Authority
BR
Brazil
Prior art keywords
sag
apoptosis
protein
human
gene
Prior art date
Application number
BR9813757-3A
Other languages
English (en)
Inventor
Yi Sun
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR9813757A publication Critical patent/BR9813757A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Abstract

Patente de Invenção: <B>''SAG: SENSìVEL A GENE DE APOPTOSE''<D>. A presente invenção apresenta novos genes e polipeptídeos derivados dos mesmos que codificam uma proteína sensível a redox que promovem o crescimento de células, protegem as células contra a apoptose, limpam os radicais de oxigêniio e podem ser usados para a reversão de um fenótipo de tumor. Em uma tentativa de identificar o(s) gene(s) responsável(eis) por apoptose induzida por 1,10-fenantrolina (OP) em células tumurosas, foi empregada uma técnica de exibição diferencial e clonado um gene induzível por OP, SAG (Gene Sensível à Apoptose). O SAG codifica uma nova proteína de ligação heme sensível a redox com um domínio de dedo ANEL de zinco. A proteína de SAG consiste em 113 aminoácidos com um peso molecular calculado de 12,7 kDa. A homologia de seq³ência procura revelar que o SAG é altamente conservado entre as espécies, sugerindo a sua importãncia funcional. Essa sugestão é demonstrada pela verificação que a ruptura do SAG na levedura é letal. Dois mutantes de deleção de SAG foram detectados nas linhagens de células de câncer humano originárias do cólon e dos testículos sugerindo o seu possível papel na carcinogênese humana. A superexpressão da proteína de SAG e, uma linhagem de carcinoma do cólon humano, DLD1, e uma linhagem de neuroblastoma humano, SY5Y, protege as células contra a apoptose induzida por OP, íons de cobre e zinco. Além disso, a transfecção de SAG anti-sentido inibe certos fenótipos de células tumurosas em linhagem de célula humana DLD1 e a microinjeção de RNA de SAG estimula o crescimento de células. é proposto que a proteína de SAG é uma molécula de proteção celular que funciona como um sensor de redox para tamponar o dano induzido por estresse oxidativo, bem como um fator de crescimento para estimular o crescimento de células. A proteína de SAG vai ser um alvo molecular ideal no desenvolvimento de drogas contra distúrbios neurodegenerativos, cânceres, distrofia muscular, e da promoção de cura de feridas.
BR9813757-3A 1997-12-19 1998-12-15 Sag : sensìvel a gene de apoptose BR9813757A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6817997P 1997-12-19 1997-12-19
US9984098P 1998-09-11 1998-09-11
PCT/US1998/026705 WO1999032514A2 (en) 1997-12-19 1998-12-15 Sag: sensitive to apoptosis gene

Publications (1)

Publication Number Publication Date
BR9813757A true BR9813757A (pt) 2000-10-03

Family

ID=26748669

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9813757-3A BR9813757A (pt) 1997-12-19 1998-12-15 Sag : sensìvel a gene de apoptose

Country Status (8)

Country Link
EP (1) EP1044217A2 (pt)
JP (1) JP2001526063A (pt)
KR (1) KR20010033299A (pt)
AU (1) AU765741B2 (pt)
BR (1) BR9813757A (pt)
CA (1) CA2303483A1 (pt)
NZ (1) NZ503417A (pt)
WO (1) WO1999032514A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078203B1 (en) 1999-03-31 2006-07-18 The University Of North Carolina At Chapel Hill Isolated DNA encoding cullin regulators ROC1 and ROC2, isolated proteins encoded by the same, and methods utilizing the same
WO2000058472A2 (en) * 1999-03-31 2000-10-05 The University Of North Carolina At Chapel Hill Isolated dna encoding cullin regulators roc1 and roc2, isolated proteins encoded by the same, and methods utilizing the same
WO2001046468A2 (en) * 1999-12-21 2001-06-28 Eirx Therapeutics Ltd Screening method for ros-induced apoptosis in a cell
US6740495B1 (en) 2000-04-03 2004-05-25 Rigel Pharmaceuticals, Inc. Ubiquitin ligase assay
US6979551B2 (en) 2000-04-03 2005-12-27 Rigel Pharmaceuticals, Inc. Assays for identifying ubiquitin agents and for identifying agents that modify the activity of ubiquitin agents
DE60119524T2 (de) * 2000-07-07 2007-05-03 Eirx Therapeutics Ltd. Screening-verfahren
NZ526101A (en) 2000-12-22 2005-06-24 Janssen Pharmaceutica Nv Genes for drug target identification in yeast and fungi i.e. candida that are involved in apoptosis
CN115345122B (zh) * 2022-08-31 2023-03-17 沐曦科技(北京)有限公司 一种用于仿真的非标准总线协议的芯片验证装置

Also Published As

Publication number Publication date
KR20010033299A (ko) 2001-04-25
WO1999032514A2 (en) 1999-07-01
NZ503417A (en) 2002-12-20
EP1044217A2 (en) 2000-10-18
WO1999032514A3 (en) 1999-09-10
AU765741B2 (en) 2003-09-25
CA2303483A1 (en) 1999-07-01
AU1918099A (en) 1999-07-12
JP2001526063A (ja) 2001-12-18

Similar Documents

Publication Publication Date Title
Stefanetti et al. Recent advances in understanding the role of FOXO3
Jin et al. BRCA1 activation of the GADD45 promoter
Marmolino et al. PGC-1alpha down-regulation affects the antioxidant response in Friedreich's ataxia
Trougakos The molecular chaperone apolipoprotein J/clusterin as a sensor of oxidative stress: implications in therapeutic approaches-a mini-review
Fatma et al. Transcriptional regulation of the antioxidant protein 2 gene, a thiol-specific antioxidant, by lens epithelium-derived growth factor to protect cells from oxidative stress
Margue et al. Transcriptional modulation of the anti-apoptotic protein BCL-XL by the paired box transcription factors PAX3 and PAX3/FKHR
Huang et al. Long non-coding RNA MEG3 induces cell apoptosis in esophageal cancer through endoplasmic reticulum stress
Miyakawa et al. Tonicity-responsive enhancer binding protein, a rel-like protein that stimulates transcription in response to hypertonicity
Unoki et al. Novel splice variants of ING4 and their possible roles in the regulation of cell growth and motility
Tan et al. MAP-1 is a mitochondrial effector of Bax
Lin et al. Heme oxygenase-1 protein localizes to the nucleus and activates transcription factors important in oxidative stress
Zheng et al. Hemocyanin from shrimp Litopenaeus vannamei has antiproliferative effect against HeLa cell in vitro
Jafarnejad et al. Regulation of p53 by ING family members in suppression of tumor initiation and progression
Shen et al. Distinct domains for anti-and pro-apoptotic activities of IEX-1
Gillardon et al. Expression of nuclear redox factor ref-1 in the rat hippocampus following global ischemia induced by cardiac arrest
Kudchadkar et al. Advances in the treatment of Basal cell carcinoma: Hedgehog inhibitors
Zhang et al. Tetrahydrocurcumin induces mesenchymal-epithelial transition and suppresses angiogenesis by targeting HIF-1α and autophagy in human osteosarcoma
Davidson et al. Differential regulation of p53 function by the N-terminal ΔNp53 and Δ113p53 isoforms in zebrafish embryos
BR9813757A (pt) Sag : sensìvel a gene de apoptose
Ishiguchi et al. ZNF143 activates gene expression in response to DNA damage and binds to cisplatin‐modified DNA
He et al. Identification of Aurora-A as a direct target of E2F3 during G2/M cell cycle progression
Hwang et al. The roles of multifunctional protein ErbB3 binding protein 1 (EBP1) isoforms from development to disease
Theiss et al. Interleukin-6 transcriptionally regulates prohibitin expression in intestinal epithelial cells
Godic et al. Four novel ATP2A2 mutations in Slovenian patients with Darier disease
Bendesky et al. p53 codon 72 polymorphism, DNA damage and repair, and risk of non-melanoma skin cancer

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DA(S) 8 A, 9A E 10A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 1986 DE 27/03/2009.